Titre :
  • Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.
Auteur : van Cutsem, Eric ; Vervenne, Walter L ; Bennouna, Jaafar ; Humblet, Yves ; Gill, Sharlene ; Van Laethem, Jean-Luc ; Verslype, Chris ; Scheithauer, Werner ; Shang, Aijing ; Cosaert, Jan ; Moore, Malcolm J
Informations sur la publication : Journal of clinical oncology, 27, 13, (page 2231-2237)
Statut de publication : Publié, 2009-05
Sujet CREF : Sciences bio-médicales et agricoles
Mots-clés MeSH : Antibodies, Monoclonal -- administration & dosage -- adverse effects
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
Deoxycytidine -- administration & dosage -- adverse effects -- analogs & derivatives
Humans
Neoplasm Metastasis
Pancreatic Neoplasms -- drug therapy -- mortality -- pathology
Quinazolines -- administration & dosage -- adverse effects
Note : Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langue :
  • Anglais
Identificateurs : urn:issn:0732-183X 
info:doi/10.1200/JCO.2008.20.0238
info:pii/JCO.2008.20.0238
info:pmid/19307500